false 0001029125 0001029125 2024-05-28 2024-05-28
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
 
FORM 8-K
CURRENT REPORT
 
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
 
May 28, 2024
Date of Report (Date of Earliest Event Reported)
 
Panbela Therapeutics, Inc.
(Exact Name of Registrant as Specified in its Charter)
 
Delaware
  
001-39468
  
88-2805017
(State of Incorporation)
  
(Commission File Number)
  
(I.R.S. Employer Identification No.)
 
712 Vista Blvd #305
Waconia, Minnesota
  
55387
(Address of Principal Executive Offices)
  
(Zip Code)
 
(952) 479-1196
(Registrant’s Telephone Number, Including Area Code)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
Securities registered pursuant to Section 12(b) of the Act: None.
 
Securities registered pursuant to Section 12(g) of the Act: Common Stock, $0.001 par value
 
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.
Emerging growth company ☐
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
 
 
 
 
Item 5.07.         Submission of Matters to a Vote of Security Holders.
 
Panbela Therapeutics, Inc. (the “Company”) held a special meeting of stockholders on May 28, 2024. The following proposals, each as described further in the definitive proxy statement for the meeting filed with the Securities and Exchange Commission on May 6, 2024, were voted upon by the stockholders:
 
Proposal 1 – Reverse Stock Split
 
Stockholders approved the amendment to the Company’s Amended and Restated Certificate of Incorporation to effect a reverse stock split of our outstanding common stock, par value $0.001 per share, at a reverse stock split ratio ranging from any whole number between 1-for-10 and 1-for-45, subject to and as determined by the Board of Directors, based on the votes listed below:
 
For
  
Against
  
Abstain
47,410,136
  
44,904,765
  
28,979
 
 
Proposal 2 – Adjournment
 
Stockholders approved the adjournment of the special meeting to a later date or dates if necessary to solicit additional proxies if there are insufficient votes at the time of the special meeting to approve Proposal 1 in the absence of quorum, based on the votes listed below:
 
For
  
Against
  
Abstain
  
Broker Non-Votes
1,066,313
  
1,041,720
  
24,396
  
211,451
 
Although Proposal 2 was approved, adjournment of the special meeting was not necessary or appropriate because a quorum was present and the Company’s stockholders approved Proposal 1. The Board has not determined the timing or ratio for a reverse stock split, if any.
 
 
 
 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Current Report to be signed on its behalf by the undersigned hereunto duly authorized.
 
Panbela Therapeutics, Inc.
Date: May 29, 2024 
By:
/s/ Susan Horvath
Susan Horvath
Chief Financial Officer
 
 
 
 
 
v3.24.1.1.u2
Document And Entity Information
May 28, 2024
Document Information [Line Items]  
Entity, Registrant Name Panbela Therapeutics, Inc.
Document, Type 8-K
Document, Period End Date May 28, 2024
Entity, Incorporation, State or Country Code DE
Entity, File Number 001-39468
Entity, Tax Identification Number 88-2805017
Entity, Address, Address Line One 712 Vista Blvd #305
Entity, Address, City or Town Waconia
Entity, Address, State or Province MN
Entity, Address, Postal Zip Code 55387
City Area Code 952
Local Phone Number 479-1196
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity, Emerging Growth Company false
Amendment Flag false
Entity, Central Index Key 0001029125
Panbela Therapeutics (NASDAQ:PBLA)
Gráfica de Acción Histórica
De May 2024 a Jun 2024 Haga Click aquí para más Gráficas Panbela Therapeutics.
Panbela Therapeutics (NASDAQ:PBLA)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024 Haga Click aquí para más Gráficas Panbela Therapeutics.